Furthermore, the PD-L1 inhibitor durvalumab is being tested as standalone immunotherapy in cohorts of patients affected by esophageal cancer or (NCT01938612).[34] Phase II clinical trials (NCT02923934 and NCT02829918) of nivolumab as PD-1 immune checkpoint inhibitor for BTCs are in preparation. This evidence concerns the gene CD274 and esophageal cancer.